Leap Therapeutics Presents Positive DKN-01 Clinical Data in Biliary Tract Cancers at American Society of Clinical Oncology (ASCO) 2017 Annual Meeting
Leap Therapeutics, Inc. (LPTX)
Last leap therapeutics, inc. earnings: 11/14 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.leaptx.com
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., May 17, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported interim data from the Phase 1 study of DKN-01 in combination with standard of care chemotherapy in patients with advanced biliary tract cancers. Data from the study was published online as an abstract in advance of a poster presentation being held at the American Society of Clinical Oncology (ASCO) Annual Meeting held June 2 - 6, 2017 in Chicago, Illinois. “These data combining DKN-01 with gemcitabine and cisplatin are highly encouraging and provide a strong rationale for advanced clinical development. Biliary tract cancer is an aggressive disease with a poor prognosis and for which there are limited treatment options. First-line chemotherapy studies have reported response rates of 20% to 25%, progression-free survival of 5.6 to eight months, and overall survival of 11 to 12 months,” commented Jenni
Show less
Read more
Impact Snapshot
Event Time:
LPTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LPTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LPTX alerts
High impacting Leap Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LPTX
News
- Leap Therapeutics Announces $40 Million Private Placement [Yahoo! Finance]Yahoo! Finance
- Leap Therapeutics Announces $40 Million Private PlacementPR Newswire
- Leap Therapeutics, Inc. (NASDAQ: LPTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- Leap Therapeutics, Inc. (NASDAQ: LPTX) had its price target lowered by analysts at Robert W. Baird from $11.00 to $9.00. They now have an "outperform" rating on the stock.MarketBeat
- Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
LPTX
Earnings
- 3/18/24 - Beat
LPTX
Sec Filings
- 4/19/24 - Form SC
- 4/19/24 - Form 3
- 4/11/24 - Form 8-K
- LPTX's page on the SEC website